Zimmer Biomet completed the acquisition of Paragon 28 for $1.2bn.

Zimmer Biomet, a global medical technology provider, completed the acquisition of Paragon28, a medical device company, for $1.2bn. "We look forward to building on the strong foundation set by Albert DaCosta and the Paragon 28 team and are excited to officially welcome them to the Zimmer Biomet family. This combination expands our leadership in the foot and ankle segment, one of the highest growth specialties in musculoskeletal care. Together, we will drive innovation at scale and leverage the power of Paragon 28's dedicated foot and ankle commercial channel to help advance our Mission to alleviate pain and improve the quality of life for people around the world," Ivan Tornos, Zimmer Biomet President and CEO.